CLAIMS

1. A pharmaceutical composition comprising an open matrix network carrying one or more pharmaceutically active ingredients, wherein the open matrix network is a matrix of water-soluble or water-dispersible carrier material having interstices dispersed throughout and comprises maltodextrin and hyaluronic acid or a pharmaceutically acceptable salt thereof, wherein the maltodextrin constitutes 40 to 99% by weight, based on the total weight of the open matrix network and material carried by the open matrix network, and wherein the pharmaceutical composition disintegrates in an aqueous medium within 30 seconds.

2. The pharmaceutical composition according to claim 1 wherein the hyaluronic acid has an average molecular weight in the range from 1×10^4 to 1×10^7 dalton, preferably an average molecular weight of $3 \times 10^6 \pm 0.6 \times 10^6$ dalton.

3. The pharmaceutical composition according to claim1 or 2 having a tensile strength of at least 0.1 N/mm^2.

4. The pharmaceutical composition according to any one of claims 1-3, wherein the open matrix network and material carried by the open matrix network comprise 40 to 99% by weight maltodextrin and 0.99 to 5% by weight hyaluronic acid or a pharmaceutically acceptable salt thereof, based on the total weight of the open matrix network and material carried by the open matrix network.

5. The pharmaceutical composition according to any one of claims 1-3, wherein the open matrix network and material carried by the open matrix network comprise 50 to 98% by weight maltodextrin and 0.99 to 3% by weight hyaluronic acid or a pharmaceutically acceptable salt thereof, based on the total weight of the open matrix network and material carried by the open matrix network.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the composition disintegrates in an aqueous medium within 10 seconds.

7. The pharmaceutical composition according to any one of claims 1-6, which is in an oral dosage form.

8. The pharmaceutical composition according to claim 7 which is adapted for sublingual administration.

9. The pharmaceutical composition according to any one of claims 1-8, wherein the active ingredient is desmopressin, desmopressin acetate, montelukast, montelukast sodium, sildenafil, sildenafil citrate, silodosin or tadalafil.

10. The pharmaceutical composition according to any one of claims 1-9 obtainable by subliming a solvent from a solidified liquid preparation comprising the active ingredient, maltodextrin and hyaluronic acid or a pharmaceutically acceptable salt thereof in a solvent.

11. A process for preparing the pharmaceutical composition as defined in claim 1, the process comprising subliming the solvent from a solidified liquid preparation comprising one or more pharmaceutically active ingredients, maltodextrin and hyaluronic acid or a pharmaceutically acceptable salt thereof in a solvent.

12. The process according to claim 11, comprising: (a) introducing unit dosage quantities of said liquid preparation into depressions of an open blister pack; (b) solidifying the liquid preparation; and (c) subliming the solvent from the solidified preparation to obtain solid unit dosage forms within said depressions.

13. The process according to claim 11 or 12, wherein the solvent is water.

14. The process according to any one of claims 11-13, wherein the active ingredient is desmopressin, desmopressin acetate, montelukast, montelukast sodium, sildenafil, sildenafil citrate, silodosin or tadalafil.

.